![]() Data may be intentionally delayed pursuant to supplier requirements. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Source: FactSetĭata are provided 'as is' for informational purposes only and are not intended for trading purposes. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Sources: FactSet, Tullett PrebonĬommodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Sources: FactSet, Tullett PrebonĬurrencies: Currency quotes are updated in real-time. Sources: FactSet, Dow Jonesīonds: Bond quotes are updated in real-time. Sources: FactSet, Dow JonesĮTF Movers: Includes ETFs & ETNs with volume of at least 50,000. Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Overview page represent trading in all U.S. Indexes: Index quotes may be real-time or delayed as per exchange requirements refer to time stamps for information on any delays. Copyright 2019© FactSet Research Systems Inc. Fundamental company data and analyst estimates provided by FactSet. International stock quotes are delayed as per exchange requirements. stock quotes reflect trades reported through Nasdaq only comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. ![]() Additionally, the company has initiated HARMONY trial of BLU-701 in EGFR-driven lung cancer, with initial data expected in 2H22.Stocks: Real-time U.S.It expects to report topline data from the registration-enabling Part 2 of the PIONEER trial of AYVAKIT in non-advanced SM in mid-2022 initiate clinical trials of BLU-451 (formerly LNG-451) in EGFR exon 20 insertion positive lung cancer and BLU-222 in cyclin E aberrant cancers in Q122 and present initial SYMPHONY trial data for BLU-945 in EGFR-driven lung cancer in 1H22. In addition to the financial update, Blueprint Medicines outlined key strategies and goals for 2022.The firm expects existing cash, cash equivalents and investments, together with anticipated future product revenues, to provide sufficient capital to achieve a self-sustainable financial profile.demand in advanced systemic mastocytosis. The results were driven by strong initial U.S. Global product revenues for AYVAKIT, a treatment for adults with advanced systemic mastocytosis, were approximately $20M (~+230% Y/Y) in Q4 and $52.9M (+150% Y/Y) in FY21.Consensus revenue estimates for the year is $172.26M. The precision therapy company expects FY21 revenues, including collaboration revenues, to be at the higher-end of previous guidance of $170-$180M.Blueprint Medicines ( BPMC -4.6%) shares have slumped after the company provided preliminary financial results for Q4 and full year 2021.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |